Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02844439 · ClinicalTrials.gov registry record · Phase 2
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02844439 is a Phase 2 study that has completed, run by Kadmon Corporation. The registered enrollment target is 40 participants.
The verdict
NCT02844439, a Phase 2 study, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.
Interventions
- DRUG Tesevatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02844439
The ClinicalTrials.gov registry entry for NCT02844439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tesevatinib is the first listed.
NCT02844439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02844439 about?
NCT02844439 is a clinical study titled "Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma". This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.
What is the current status of trial NCT02844439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2016-06. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT02844439?
The interventions under investigation include: Tesevatinib (DRUG).
Who is sponsoring clinical trial NCT02844439?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.